FDA Signs Off On Botox Warning; Changes Generic Name

The Food and Drug Administration said Monday it approved a new warning on Allergan Inc.’s AGN Botox and a similar product about the possibility of life-threatening breathing and swallowing problems, following up on an earlier announcement about tougher warnings.

Along with signing off on a boxed warning for Botox and Myobloc, made by Solstice Neurosciences Inc., a private firm in Malvern, Pa., the agency said it was changing the generic names for both products to avoid medication errors.

Read full story via WSJ.com.

Short URL: http://www.plasticsurgeonsnews.com/?p=362

Posted by admin on Aug 4 2009. Filed under Injectables. You can follow any responses to this entry through the RSS 2.0. You can leave a response or trackback to this entry